Desentum is a biotechnology company in Finland developing an allergy vaccine that harnesses the immune system.
Desentum has raised $31.4M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2026.
Desentum's investors include European Innovation Council, Springvest, Cascara Ventures, VTT Ventures, Luxembourgian ACME Investments.
Desentum is headquartered in Espoo, Finland.
Desentum is a biotechnology company in Finland developing an allergy vaccine that harnesses the immune system.
Desentum is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Desentum — Funding & Investors." VCBacked, October 12, 2026, https://www.vcbacked.co/company/desentum. Accessed November 14, 2026.
VCBacked. (2026). Desentum — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/desentum
{{cite web |title=Desentum — Funding & Investors |url=https://www.vcbacked.co/company/desentum |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Desentum? Request a listing update